Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-26T05:56:13.907Z Has data issue: false hasContentIssue false
  • English
  • Français

Cerebral Glucose and Dopa Metabolism in Movement Disorders

Published online by Cambridge University Press:  05 January 2016

W.R. Wayne Martin  and
Michael R. Hayden
W.R. Wayne Martin*
Affiliation:
Departments of Medicine (Neurology), and Medical Genetics, University of British Columbia, Vancouver
Michael R. Hayden
Affiliation:
Departments of Medicine (Neurology), and Medical Genetics, University of British Columbia, Vancouver
*
U.B.C. Health Sciences Centre Hospital,2211 Wesbrook Mall, Vancouver, B.C., Canada V6T 1W5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The development of positron emission tomography (PET) has enabled us to perform in vivo measurements of certain aspects of regional cerebral function. Regional cerebral glucose metabolism may be readily quantified with [18F] fluoro-2-deoxyglucose (FDG) and presynaptic dopaminergic function may be studied with the labelled dopa analog 6-[18F] fluoro-L-dopa. We have applied a model to the analysis of 6-FD/PET data with which in vivo age-related changes in dopaminergic function may be demonstrated in normal subjects. With this technique, we have studied a series of asymptomatic MPTP-exposed subjects and have shown evidence of subclinical nigrostriatal pathway damage. Studies of regional cerebral glucose metabolism with FDG in early Huntington's disease have shown a characteristic impairment in caudate function which precedes the development of caudate atrophy. In addition, some asymptomatic individuals who are at risk for HD have caudate hypometabolism. We feel that, at the present time, PET provides information which is complementary to the clinical examination in establishing a diagnosis of HD. In the future these studies may also help in the investigation of at risk individuals

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 448 - 451
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Garnett, ES, Firnau, G, Nahmias, C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305: 137–138.CrossRefGoogle ScholarPubMed
2.Garnett, ES, Firnau, G, Nahmias, C, et al. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 1983; 280: 169–171.CrossRefGoogle ScholarPubMed
3.Firnau, G, Garnett, ES, Sourkes, TL, et al. [18F]Fluoro-dopa: a unique gamma-emitting substrate for dopa decarboxylase. Experientia 1975; 31: 1254–1255.CrossRefGoogle Scholar
4.Cumming, P, Boyes, BE, Martin, WRW, et al. The metabolism of [l8F]-6-fluoroL-dopa in the hooded rat. J Neurochem 1987; 48; 601–608.Google Scholar
5.Chiueh, CC, Zukowska-Grojec, Z, Kirk, KL, et al. 6-Fluoro-catecholamines as false adrenergic neurotransmitters. J Pharmacol Exp Ther 1983; 225: 529–533.Google ScholarPubMed
6.Chiueh, CC, Kirk, KL, Channing, MA, et al. Neurochemical basis for the use of 6F-DOPA for visualizing dopamine neurons in the brain by positron emission tomography. Soc Neurosci Abstrs 1984; 14: 883.Google Scholar
7.Leenders, KL, Poewe, WH, Palmer, AJ, et al. Inhibition of L-[18F] fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986; 20: 258–261.CrossRefGoogle ScholarPubMed
8.Garnett, ES, Firnau, G, Nahmias, C, et al. Blood-brain barrier transport and cerebral utilization of dopa in living monkeys. Am J Physiol 1980; 238: 318–327.Google ScholarPubMed
9.Patlak, CS, Blasberg, RG, Fenstermacher, JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metabol 1983; 3: 1–7.CrossRefGoogle ScholarPubMed
10.Martin, WRW, Boyes, BE, Leenders, KL, et al. Method for the quantitative analysis of 6-fluorodopa uptake data from positron emission tomography. J Cereb Blood Flow Metabol 1985; 5(Suppl. 1): S593–S594.Google Scholar
11.Boyes, BE, Cumming, P, Martin, WRW, et al. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 1986; 39: 2243–2252.CrossRefGoogle ScholarPubMed
12.McGeer, PL, McGeer, EG, Suzuki, JS. Aging and extrapyramidal function. Arch Neurol 1977; 34: 33–35.CrossRefGoogle ScholarPubMed
13.Nahmias, C, Garnett, ES, Firnau, G, et al. Striatal dopamine distribution in Parkinsonian patients during life. J Neurol Sci 1985; 69: 223–230.CrossRefGoogle ScholarPubMed
14.Martin, WRW, Stoessl, AJ, Adam, MJ, et al. Positron emission tomography in Parkinson’s disease: glucose and dopa metabolism: In: Yahr, M, Bergmann, K, eds. Parkinson’s disease. Advances in Neurology, Vol. 45. New York; Raven Press 1986; 95–98Google Scholar
15.Leenders, KL, Palmer, AJ, Quinn, N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatr 1986; 49: 853–860.CrossRefGoogle ScholarPubMed
16.Homykiewicz, O. Brain neurotransmitter changes in Parkinson’s disease. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London: Butterworth Scientific 1981; 41–58.CrossRefGoogle Scholar
17.Davis, GC, Williams, AC, Markey, SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr Res 1979; 1: 249–254.CrossRefGoogle ScholarPubMed
18.Burns, RS, Chiueh, CC, Markey, SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 1983; 80:4546–4550.CrossRefGoogle ScholarPubMed
19.Langston, JW, Ballard, P, Tetrud, JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle ScholarPubMed
20.Calne, DB, Langston, JW. Aetiology of Parkinson’s disease. Lancet 1983,31: 1457–1459.CrossRefGoogle Scholar
21.Calne, DB, Langston, JW, Martin, WRW, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 1985; 317: 246–248.CrossRefGoogle Scholar
22.Martin, WRW, Stoessl, AJ, Adam, MJ, et al. Imaging of dopamine systems in human subjects exposed to MPTP. In: Markey, SP, Castagnoli, N, Trevor, AJ, Kopin, IJ, eds. MPTP: A neurotoxin producing a parkinsonian syndrome. Orlando: Academic Press 1986; 315–325.Google Scholar
23.Sokoloff, L, Reivich, M, Kennedy, C, et al. The [l4C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897–916.CrossRefGoogle ScholarPubMed
24.Phelps, ME, Huang, SC, Hoffman, EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371–388.CrossRefGoogle ScholarPubMed
25.Kuhl, DE, Phelps, ME, Markham, CH, et al. Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 12: 425–434.CrossRefGoogle ScholarPubMed
26.Hayden, MR, Martin, WRW, Stoessl, AJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology 1986; 36: 888–894.CrossRefGoogle ScholarPubMed
27.Young, AB, Penney, JB, Starosta-Rubinstein, S, et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20: 296–303.CrossRefGoogle ScholarPubMed
28.Suchowersky, O, Hayden, MR, Martin, WRW, et al. Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders 1986; 1: 33–44.CrossRefGoogle ScholarPubMed
29.Palella, TD, Hichwa, RD, Ehrenkaufer, RC, et al. l8F-fluorodeoxy-glucose PET scanning in HPRT deficiency. Am J Hum Genet 1985; 37: A70.19.Google Scholar
30.Guttman, M, Lang, AE, Garnett, S, et al. No consistent abnormality of FDG scanning in SLE chorea: further evidence that striatal hypometabolism is not the correlate of chorea. Neurology 1986; 36(suppl.l): 309.Google Scholar
31.Kuhl, DE, Markham, CH, Metter, EJ, et al. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington’s disease. In: Sokoloff, L, ed. Brain Imaging and Brain Function. New York: Raven Press 1985; 199–209.Google Scholar
32.Mazziotta, JC, Phelps, ME, Pahl, J, et al. Caudate hypometabolism in asymptomatic subjects at risk for Huntington’s disease. J Nucl Med 1986; 27: 920.Google Scholar
33.Young, AB, Penney, JB, Starosta-Rubinstein, S, et al. Persons at risk for Huntington’s disease: brain metabolism determined with l8F-FDG. J Nucl Med 1986; 27: 920.Google Scholar
34.Hayden, MR, Hewitt, J, Stoessl, AJ, et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington disease. Neurology 1987 (in press).CrossRefGoogle Scholar